Clinical trial Recruiting at 1 site Interventional Ages 18 to 85

Acellular Dermal Matrix vs. Resorbable Collagen Barrier for Guided Bone Regeneration

Official title: A Prospective, Double-Arm, Randomized Controlled Trial Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix Compared to Resorbable Collagen Membranes in Edentulous Ridge Augmentation

Run by University of Alabama at Birmingham · NCT07613047 · Data updated 2026-11-12

This study compares an acellular dermal matrix barrier to a resorbable collagen membrane to see which works better for building width in horizontal ridge augmentation before implants.

Quick facts

Study typeInterventional
Ages18 Years to 85 Years
SexAll
Enrollment70 (estimated)
SponsorUniversity of Alabama at Birmingham
Academic / other
Drugs / interventionsradiation
Locations1 site (Birmingham, Alabama)
StatusRecruiting
StartedSeptember 10, 2026
Main results expectedOctober 2027
Study endsOctober 2028
Registry record updatedOctober 23, 2026
Trial IDNCT07613047 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) who need horizontal ridge augmentation with GBR at UAB, are English-speaking, and meet dental and health criteria to receive either ADM or collagen barrier in a non-implant GBR procedure.

Probably not a fit

Patients with non-eligible anatomy, comorbidities, or those requiring immediate implants may not experience benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This investigator-initiated trial tests two barrier membranes—acellular dermal matrix (ADM) and resorbable cross-linked collagen matrix (Mem-Lok)—as part of guided bone regeneration at lateral ridge augmentation sites. Participants must be adults requiring horizontal ridge augmentation without immediate implant placement and meet specific health and dental criteria. Outcomes focus on hard- and soft-tissue results, including ridge width gains and tissue characteristics, using standardized GBR techniques with particulate grafts and barrier membranes. The study builds on prior data suggesting stable clot formation and space maintenance, while exploring potential additional soft-tissue benefits with ADM. Direct comparative data between ADM and collagen membranes in this context are limited, making this trial a key step in understanding relative performance.

Why it matters

Potential benefit: If successful, patients could experience greater or more durable ridge width gains and potentially improved soft tissue quality supporting future implants.

How similar studies have gone: Previous limited human data with ADM as a barrier showed potential hard- and soft-tissue benefits, but direct randomized comparisons to collagen barriers are scarce.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* English speaking
* At least 18 years old
* Must be a patient of the UAB Dental School
* Able to read and understand informed consent document
* Patients presenting with a diagnosed need horizontal ridge augmentation with GBR without simultaneous implant placement, to allow for future dental implant placement.
* Presence of periodontally healthy, non-carious neighboring teeth and/or healthy restored dental implants on either side of the edentulous span planned for GBR, or unhealthy adjacent teeth to be extracted during the same visit.
* ≤4 mm ridge width in a Seibert Class I Edentulous span19
* No anticipated need for surgical and/or endodontic care at planned teeth adjacent to the proposed surgical site during the study period.

Exclusion Criteria:

* Non-English speaking
* Less than 18 years old
* Smokers/nicotine users (defined as currently reporting use of any form of tobacco/nicotine products)
* Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing, including:

  * Uncontrolled diabetes (HbA1c \> 7%)
  * Untreated periodontal disease
  * History of head/neck radiation
  * IV bisphosphonates
  * Immunocompromised state
  * Pregnancy
  * Acute infection at site
* Documented or suspected allergy or sensitivity to any study product

Where it's running

  • University of Alabama at Birmingham
    Birmingham, Alabama, United States
    Recruiting

Study contacts

  • Principal investigator: Maria L Geisinger, DDS, MS — University of Alabama at Birmingham
  • Study coordinator: Maria Geisinger, DDS, MS
  • Email: miagdds@uab.edu
  • Phone: 205-934-4984

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.